Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05481346
Other study ID # UALBIO2022/011
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 28, 2022
Est. completion date December 30, 2022

Study information

Verified date July 2022
Source Universidad de Almeria
Contact Pablo Jorge Marcos Pardo, PhD
Phone +34 950214791
Email pjmarcos@ual.es
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The current study aims to determine the effect of a multidomain intervention (physical fitness, motivational and cognitive training) on body composition, sarcopenia, cardiovascular health, physical fitness, functional capacity, quality of life, frailty, emotional state and cognitive status in elderly participants, through a randomized controlled trial, to determine its suitability and recommend it as a preventive and health strategy for community-dwelling older adults.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date December 30, 2022
Est. primary completion date September 18, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 55 Years to 90 Years
Eligibility Inclusion Criteria: 1. Subject has provided written and dated informed consent to participate in the study. 2. Subject is a male or female between 55 and 90 years of age, inclusive. 3. Subject is in good health as determined by a health history questionnaire and has been provided clearance from their personal physician. 4. Subject is untrained in resistance and aerobic exercise (does not participate in structured physical activity, including walking, more than 3 times per week). 5. Ability to walk independently without any gait aid Exclusion Criteria: 1. Perform high-intensity aerobic exercise on a consistent basis (>180 min-week). 2. Be performing some other regular and systematic strength training program during the intervention in the first half of 2022. 3. Have a body mass index greater than 35. 4. Have a diagnosis of ischemic heart disease. 5. Have a diagnosis of severe aortic stenosis, uncontrolled arrhythmias, decompensated heart failure or acute myocarditis. 6. Possess uncontrolled blood pressure (TAS >180 and TAD >110). 7. Stroke. 8. Severe peripheral arterial disease. 9. Other illnesses such as recent thromboembolic disease, aortic aneurysm, clinically significant renal or hepatic insufficiency, severe COPD, clinically significant acute infections, severe psychiatric illness, uncontrolled metabolic disease, limiting locomotor pathology or musculoskeletal disease worsened by exercise, hormone therapy at the time or one year prior, being a woman with surgical menopause. 10. Other pathologies that contraindicate the practice of physical exercise, collected in the previous medical examination that all participants must undergo.

Study Design


Intervention

Procedure:
Multidomain training
The training program has a duration of 18 weeks with 2 training sessions per week. The training will have a gradual progression of intensity. One day they train two blocks of strength and one block of cognitive exercises and on the second day, they train one block of power, one block of strength+cognitive and one block of aerobic training. All sessions are 60 minutes long (10 minutes of warm-up, 40 minutes of training and 10 minutes of cool-down). Classes are in small groups of no more than 8 members.

Locations

Country Name City State
Spain Pablo Jorge Marcos Pardo Almería

Sponsors (1)

Lead Sponsor Collaborator
Universidad de Almeria

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Body Weight in Kilograms was measured after removal of shoes and heavy outer clothing, using a Tanita BC-418 MA or InBody equipment to the nearest 0.1 kg. Change from Baseline body weight (kg) at 18 weeks
Primary Height in Meters Standing height without shoes was measured using a Seca 202 stadiometer (Seca, Hamburg, Germany) to the nearest 0.1 cm. Change from Baseline standing height (cm) at 18 weeks
Primary Body Mass Index (BMI) was calculated as the ratio of weight to squared height in kg/m^2 Change from Baseline Body Mass Index (BMI): (kg/m^2) at 18 weeks
Primary % Fat Mass % fat mass was measured after removal of shoes and heavy outer clothing, using a Tanita BC-418 MA or InBody equipment to the nearest 0.1 kg. Change from Baseline bioelectrical impedance % fat mass at 18 weeks
Primary Muscle quality sarcopenia Sarcopenia will be assessed taking into account the reference values established for muscle quality. The muscle quality will be measure by hand grip strength test. This test will be performance with manual dynamometry (TKK 5401; Scientific Instruments Co., Ltd., Tokyo, Japan). Maximal isometric upper limb strength will be performance by maximal isometric strength. Upper strength will be register by kilogrammes. Higher value show high strength. Change from Baseline to 18 weeks
Secondary Change Blood pressure Blood pressure and heart rate will be assessed by means of an automatic device (Colin BP 880, Inc., Tampa, FL). This is noninvasive technique. The result will be register in millimeters of mercury (bood pressure) and number of pulse per minutes (heart rate). Change from Baseline to 18 weeks
Secondary Change Chair stand test Chair stand test measure the functional capacity. This is a easy physical test. This test measures the functionality of getting up and sitting down from a chair five times. The participant have to performance the test as faster as possible. The total time is recorded in seconds. A better time indicates better functional ability. Change from Baseline to 18 weeks
Secondary Change Upper and Lower strength Maximal isometric upper limb strength will be performance by maximal isometric strength of knee extension and biceps flexion with load cell. Maximal isometric lower limb will be registered in newton. Higher value show high strength. Change from Baseline to 18 weeks
Secondary Health-related quality SF-36 quality of life questionnaire Change from Baseline to 18 weeks
Secondary Cardiorrespiratory 6 minutes walk test cardiorespiratory endurance test that evaluates the distance covered in 6 minutes. Change from Baseline to 18 weeks
Secondary Change heart rate Heart rate will be assessed by means of an automatic device (Colin BP 880, Inc., Tampa, FL). This is noninvasive technique. The result will be register in number of pulse per minutes (heart rate). Change from Baseline to 18 weeks
Secondary Gait speed Gait speed will be measure by 4. 6 and 10 meter test. This is easy physical test in with the participant have to walk 4. 6 and 10 metres as faster as possible. The result will be register in seconds. Less time indicates better functional ability. Change from Baseline to 18 weeks
Secondary Time up and go test change Time up and go test measure the functional capacity of getting up, walking and sitting down form a chair. Participant have to performance this test as faster as possible. This is a easy physical test. Total seconds are records. Less seconds indicates better functional ability. Change from Baseline to 18 weeks
Secondary Short physical performance battery (SPPB) Short physical performance battery (SPBB) include three test (balance, chair stand test and gait speed) and report a final score. Chair stand test and gait speed were describe in other outcome. Balance test is a easy physical test. The participant must maintain three balancing positions for 10 seconds to overcome it. Each test offers a different score. Higher score show better functional capacity. Change from Baseline to 18 weeks
Secondary Fragility Frailty will be defined in relation to Fried's frailty phenotype (Fried et al., 2001), based on 5 criteria: unintentional weight loss, exhaustion, weakness, slow walking speed and low physical activity. Change from Baseline to 18 weeks
Secondary Satisfaction with life The Satisfaction with Life Scale is a 4-item instrument with a Likert-type scale ranging from 1 to 7 points measuring overall subjective happiness by means of statements in which participants rate themselves or compare themselves with others. Two items ask people to describe themselves using absolute rating criteria of their lives or rating criteria with respect to others, while the other two items present brief descriptions of happy or unhappy people and respondents are asked to indicate the degree to which they identify with that description. Change from Baseline to 18 weeks
Secondary Depression Depression will be measured through the Center for Epidemiological Studies Depression Scale-Revised (CESD-R) (Van Dam & Earleywine, 2011), is a 20-item questionnaire that can be used to measure levels of depressive symptoms among elderly participants. The CESD-R consists of 16 items of negative affect and 4 items of positive affect. Change from Baseline to 18 weeks
Secondary Cognitive flexibility the Stroop test measures the ability to classify information selectively. It consists of 3 phases and requires discerning between colors and words without making mistakes. Change from Baseline to 18 weeks
Secondary Attention test the Trail Making test will also assess flexibility of thought and visuospatial ability. It consists of joining numbers and words in a numerical sequence without error. Change from Baseline to 18 weeks
Secondary PSQ test To evaluate the factors that influence the general state of health, specifically stress. It evaluates six factors: Tension-Instability-Fatigue; Social Acceptance of Conflict; Energy and Fun; Overload; Satisfaction for self-fulfillment; Fear and anxiety. Change from Baseline to 18 weeks
Secondary TMMS-24 Trait-Meta Mood Scale (TMMS) emotional states Change from Baseline to 18 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04098172 - Evaluate the Performance and Safety of Comet Pressure Guidewire in the Measurement of FFR N/A